Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 22, 2017
Comprehensive Form 10-K reflects accounting treatment of historical Tysabri® royalty stream as a financial asset No impact on net cash flows or previously closed sale of Tysabri® Revised...
-
May 8, 2017New Directors Nominated by Starboard in Accordance With Previously Announced Agreement
Perrigo Company plc (NYSE; TASE: PRGO) today announced the appointment of Rolf A. Classon and Adriana Karaboutis to the Company's Board of Directors. Pursuant to the agreement with Starboard Value...
-
May 3, 2017
Perrigo Company plc (NYSE, TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on June 13, 2017 to shareholders of record on May 26, 2017.
-
May 2, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that search warrants were executed at the Company's corporate offices associated with an ongoing investigation by the U.S. Department of...
-
Apr 25, 2017- Tysabri® historical royalty stream determined to be a financial asset; Company to file 2016 Form 10-K, including restated fiscal 2014, fiscal 2015 and transition period 2015 audited financials and certain quarterly financial information as soon as practical
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today announced that the Company's Board of Directors, after consultation with management...
-
Mar 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced it has completed the divestiture of its rights to the royalty stream...
-
Mar 16, 2017- Continues to work with independent auditor, and expects to file its Form 10-K as soon as practical
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today commented, "We continue to make progress with our independent auditor, Ernst & Young...
-
Mar 8, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced the first-to-market launch of the over-the-counter ("OTC") store brand equivalent to Women's Rogaine® 5% minoxidil foam (minoxidil topical...
-
Mar 7, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today commented, "As previously discussed, in connection with a review for the announced...
-
Mar 1, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application referencing Eli Lilly and...
-
Feb 27, 2017
Delivered preliminary unaudited calendar year 2016 record reported net sales of $5.6 billion and adjusted net sales of $5.5 billion Unaudited calendar year 2016 preliminary reported loss per...
-
Feb 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced it has signed a definitive agreement to divest its rights to the...
-
Feb 27, 2017Appoints Ron Winowiecki as Acting CFO Following Resignation of Judy L. Brown
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced that Ron Winowiecki, Senior Vice President, Business Finance, has...
-
Feb 21, 2017
Perrigo Company plc (NYSE, TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on March 21, 2017 to shareholders of record on March 3,...
-
Feb 17, 2017
Perrigo Company plc (NYSE, TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral...
-
Feb 14, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release financial results for its fourth quarter and calendar year 2016 on Monday, February 27, 2017 at approximately 4:00 p.m....
-
Feb 7, 2017
Perrigo Company plc (NYSE; TASE: PRGO) announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for clindamycin, benzoyl peroxide...
-
Feb 7, 2017Company to Reconstitute Board with Five New Independent Directors
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has entered into an agreement with Starboard Value LP ("Starboard"), which owns approximately 6.7 percent of Perrigo's shares,...
-
Jan 24, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received U.S. Food and Drug Administration approval for its first-to-file Abbreviated New Drug Application referencing Taro...
-
Jan 10, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has changed its reporting segments to better align with the Company's organizational structure. Beginning with the fourth quarter of...
-
Dec 22, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that CEO John T. Hendrickson will present at the J.P. Morgan Global Healthcare Conference at 11:00 AM EST on Tuesday, January 10, 2017 at the...
-
Dec 20, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received approvals from the U.S. Food and Drug Administration for Abbreviated New Drug Applications referencing GlaxoSmithKline's...
-
Dec 8, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced its intention to restructure the Branded Consumer Healthcare's ("BCH") Omega Pharma Belgium business (which includes Omega Pharma Belgium NV,...
-
Nov 10, 2016
Delivered third quarter GAAP ("reported") net sales of $1.4 billion and non-GAAP ("adjusted") net sales of $1.3 billion, excluding sales of $22 million from held-for-sale businesses* Delivered...
-
Nov 10, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that as part of its ongoing business portfolio review, the Company will review strategic alternatives for the rights to the royalty stream...
-
Nov 10, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced the appointment of independent Directors Geoffrey M. Parker and Theodore R. Samuels to its Board of Directors, further enhancing its...
-
Nov 8, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on December 13, 2016 to shareholders of record on...
-
Oct 26, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its third quarter calendar year 2016 on Thursday, November 10, 2016 at approximately 6:30 a.m....
-
Sep 27, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced an exclusive licensing agreement with Highland Pharmaceuticals, LLC for its Tarex® methamphetamine ("meth") blocking technology and the...
-
Sep 12, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today acknowledged receipt of a letter from Starboard Value LP, a Perrigo shareholder. Perrigo will review the letter carefully and looks forward to a...
-
Sep 7, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the Morgan Stanley Global Healthcare Conference at 11:05 AM EDT on...
-
Sep 1, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Epiduo® Gel (adapalene and benzoyl...
-
Aug 23, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Suprep® (sodium...
-
Aug 17, 2016
Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has agreed to acquire Peachtree City, Georgia-based, Geiss, Destin & Dunn, Inc. ("GDD"), a small national distributor of...
-
Aug 10, 2016
Delivered second quarter reported (GAAP) net sales of $1.48 billion and adjusted (non-GAAP) net sales of $1.44 billion, excluding sales of $44 million from held-for-sale businesses* Delivered...
-
Aug 8, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its U.S. Vitamins, Minerals & Supplements (VMS) business to International...
-
Aug 2, 2016
Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on September 13, 2016 to shareholders of record on...
-
Jul 27, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter calendar year 2016 on Wednesday, August 10th, 2016 at approximately 6:00 a.m....
-
Jul 20, 2016Appoints John Wesolowski as Acting General Manager, Rx Pharmaceuticals
Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced the departure of Douglas Boothe,...
-
Jul 18, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that the U.S. Food and Drug Administration has approved the company's ANDA for omeprazole and sodium bicarbonate capsules, 20mg/1100mg. This...
-
Jun 21, 2016
Perrigo Company plc (NYSE: PRGO; TASE), today announced it has received final U.S. Food and Drug Administration ("FDA") clearance for three milk-based, store brand non-GMO infant formulas....
-
Jun 20, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has reached a definitive agreement to sell its U.S. Vitamins, Minerals & Supplements (VMS) business to International Vitamin...
-
Jun 16, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Mallinckrodt Pharmaceuticals' Ofirmev®...
-
Jun 16, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the 16th Annual Oppenheimer Consumer Conference at 9:05 AM EDT on...
-
Jun 13, 2016
Perrigo Company plc (NYSE: PRGO; TASE) announced that it has filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for ingenol mebutate gel (0.015% and...
-
May 31, 2016
Perrigo Company plc (NYSE: PRGO; TASE) and its partner West-Ward Pharmaceuticals Corp. today announced the U.S. Food and Drug Administration has approved, and that Perrigo has launched,...
-
May 18, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the UBS Global Healthcare Conference at 1:30 PM EDT on Tuesday, May...
-
May 16, 2016- No changes to adjusted results or adjusted guidance from original earnings release issued on May 12, 2016
The full corrected release reads as follows: PERRIGO COMPANY PLC REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Delivered record first quarter adjusted net sales of $1.34 billion excluding VMS sales of
-
May 11, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its first quarter calendar year 2016 on Thursday, May 12, 2016 at approximately 6:00 a.m. (ET)....
-
May 3, 2016
Perrigo Company (NYSE: PRGO; TASE) and its partner Allergan plc (NYSE: AGN) today announced the launch of guaifenesin 1200mg and dextromethorphan HBr 60mg extended-release tablets, the first OTC...